Leptin as clinical target

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 3, 2009, Pages 160-166

  Cai, Chunlin ^a   Shi, Fu Dong ^b   Matarese, Giuseppe ^c   La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c CNR   (Italy)

Author keywords

Leptin; Metabolism; Therapeutics

Indexed keywords

LEPTIN; LEPTIN ANTAGONIST; LEPTIN RECEPTOR; NEUROPEPTIDE Y; PARVOVIRUS VECTOR; PEPTIDE HORMONE ANTAGONIST; RECOMBINANT LEPTIN; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ALZHEIMER DISEASE; AMENORRHEA; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONGENITAL DISORDER; CROHN DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSLIPIDEMIA; ENERGY CONSUMPTION; ENTERITIS; FEMALE INFERTILITY; FEMALE STERILITY; FRACTURE; GASTROENTERITIS; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE ATRESIA; INTESTINE INFECTION; LIPID METABOLISM; LIPOATROPHY; LIPODYSTROPHY; LIVER CELL CARCINOMA; LOW BIRTH WEIGHT; METABOLIC DISORDER; METABOLIC SYNDROME X; NECROTIZING ENTEROCOLITIS; NEUROENDOCRINE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATENT; PREMATURITY; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY DISTRESS SYNDROME; REVIEW; SHORT BOWEL SYNDROME; SIGNAL TRANSDUCTION; TARGET ORGAN; ULCERATIVE COLITIS; VIRAL GENE THERAPY; WOUND HEALING;

ANIMALS; BIOMIMETICS; GENE THERAPY; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNIZATION; INFERTILITY; LEPTIN; METABOLIC DISEASES; NEOPLASMS; PATENTS AS TOPIC;

EID: 70350749884     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309789257379     Document Type: Review

References (137)

1. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371-379.
2. Lago R, Gómez R, Lago F, Gómez-Reino J, Gualillo O. Leptin beyond body weight regulation: Current concepts concerning its role in immune function and inflammation. Cell Immunol 2008; 252: 139-145.
3. Fei H, Okano HJ, Li C, et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA 1997; 94:7001-7005.
4. Procaccini C, Lourenço E, Matarese G, La Cava A. Leptin signaling: A key pathway in immune responses. Curr Signal Transduct Ther 2009; 4: 22-30.
5. Howard JK, Lord GM, Matarese G, et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 1999; 104: 1051-1059.
6. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84: 3686-3695.
7. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103.
8. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
9. Matarese G, Mantzoros C, La Cava A. Leptin and adipocytokines: Bridging the gap between immunity and atherosclerosis. Curr Pharm Des 2007;13: 3676-3680.
10. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100.
11. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol 2005; 184: 291-318.
12. Kalra SP, Kalra PS. Gene-transfer technology: A preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life expectancy. Trends Pharmacol Sci 2005; 26: 488-495.
13. Kalra SP, Ueno N, Kalra PS. Stimulation of appetite by ghrelin is regulated by leptin restraint: Peripheral and central sites of action. J Nutr 2005; 135:1331-1335.
14. Kalra SP. Central leptin insufficiency syndrome: An interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides 2008; 29: 127-138.
15. Miyanaga F, Ogawa Y, Ebihara K, et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia 2003; 46: 1329-1337.
16. Bates SH, Myers MG. The role of leptin/STAT3 signaling in neuroendocrine function: An integrative perspective. J Mol Med 2004; 82: 12-20.
17. Niswender KD, Morrison CD, Clegg DJ, et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: A key mediator of insulin-induced anorexia. Diabetes 2003; 52: 227-231.
18. La Cava A, Matarese G, Ebling F, Hahn BH. Leptin-based immune intervention: Current status and future directions. Curr Opin Investig Drugs 2003; 4: 1327-1332.
19. Palou, O.A., Segura, P.C., Oliver, V. P., Sanchez, R.J., Miralles, B. O.: US20080152696 (2008).
20. Qian, H., Gingerich, R.: US20070099824 (2007).
21. Qian, H., Gingerich, R.: US20050049184 (2005).
22. Qian, H., Gingerich, R.: US20020065217 (2002).
23. Snodgrass, R. H., Cioffi, J., Zupancic, T. J., Shafer, A. W.: US20030082612 (2003).
24. Yen, F., Bihain, B., Erickson, M. R., Fruebis, J.:US20060030530 (2006).
25. Jockers, R., Couturier, C., Uhlmann, E.:US20050009042 (2005).
26. Keith, J. C., Peeters, T. L., Depoortere, I., Assche, G. V.: US20050042200 (2005).
27. Kirwin, S. M., Funanage, V.L.: US6475984 (2002).
28. Kirwin, S. M., Funanage, V.L.: US7354896 (2008).
29. Kirwin, S. M., Funanage, V.L.: US20020015709 (2002).
30. Kirwin, S. M., Funanage, V.L.: US20030130192 (2003).
31. Kirwin, S. M., Funanage, V.L.: US20080242612 (2008).
32. Shah, S.:US6541033 (2003).
33. Al-barazanji, K. A., Arch, J. R. S., Camilleri, P., Neville, W. A.: US20020037553 (2002).
34. Al-barazanji, K. A., Arch, J. R. S., Camilleri, P., Neville, W. A.: US20030092126 (2003).
35. Grasso, P., Lee, D. W., Leinung, M.C.:US6777388 (2004).
36. Grasso, P., Lee, D. W., Leinung, M.C.:US7186694 (2007).
37. Grasso, P., Lee, D. W., Leinung, M. C.:US7208572 (2007).
38. Grasso, P., Lee, D. W., Leinung, M. C.:US20080108567 (2008).
39. Grasso, P., Lee, D. W., Leinung, M. C.: US20070162987 (2007).
40. Grasso, P., Lee, D. W., Leinung, M. C.: US20050049193 (2005).
41. Grasso, P., Lee, D. W., Leinung, M. C.:US20040043932 (2004).
42. Havel, P. J., Evans, J. L.:US20030008838 (2003).
43. Nakagawa, T., Yamanaka, M., Taiji, M.:US20030036512 (2003).
44. Becker, G. W., Hale, J. E.:US5919902 (1999).
45. Lallone, R.L.: US5830450 (1998).
46. Zhao, A. Z.:US20070218504 (2007).
47. Fagan, R. J., Gutteridge, A., Phelps, C. B., Power, C.: US20050106679 (2005).
48. Carr, F. J., Carter, G., Jones, T., Williams, S., Hamilton, A.: US20040072219 (2004).
49. Tavernier, J., Zabeau, L.:US20070292434 (2007).
50. Tavernier, J., Peelman, F.: US7423113 (2008).
51. Tavernier, J., Peelman, F.:US20060046959 (2006).
52. Fong, T. M., Huang, R.-R. C., Van Der, P.L.:US6632625 (1997).
53. Bennett, B., Matthews, W.: US6541604 (2003).
54. Bennett, B., Matthews, W.: US20030004109 (2003).
55. Gonzalez, R. R., Leavis, P. C.:US7407929 (2008).
56. Feng, L., Chen, S.,Xia, Y.:US7067472(2006).
57. Gonzalez, R.R., Leavis, P.C.:US20050250690 (2005).
58. Gonzalez, R. R., Leavis, P. C.: US20090029919 (2009).
59. Strasburger, C. J., Bidlingmaier, M., Wu, Z., Matarese, G., Ross, Richard J. M.: US20080118503 (2008).
60. Gertler, A., Callebaut, I., Djiane, J.:US7307142 (2007).
61. Gertler, A., Callebaut, I., Djiane, J.:US20060154859 (2006).
62. Slawik M, Vidal-Puig AJ. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev 2006; 5: 144-164.
63. Barbaro G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des 2007; 13: 2208-2213.
64. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879-884.
65. Farooqi IS. Monogenic human obesity. Front Horm Res 2008; 36: 1-11.
66. Myers, M.: US20030073634 (2003).
67. Gallaher, D.D., Freiburger, L.: US20030124170 (2003).
68. Zhao, A. Z: US20060206948 (2006).
69. Browne, M. J., Chapman, C.G., Clinkenbeard, H. E., Robinson, J. H.: US20020058311 (2002).
70. Kadowaki, T., Tobe, K., Suzuki, R.:US20040242485 (2004).
71. Ertl, J., Preibisch, G., Müller, G.: US6399745 (2002).
72. Stephens, T. W.:US5922678 (1999).
73. Stephens, T.W.:US5756461 (1998).
74. Cawthorne, M., Emilsson, V., Liu, Y.-l.: US20040048773 (2004).
75. Cawthorne, M., Emilsson, V., Liu, Y.-l.: US20020002181 (2002).
76. Cawthorne, M., Emilsson, V., Liu, Y.-l.:US20020160935 (2002).
77. Morsy, M. A., Gu, M. C., Zhoa, J., Caskey, T.C.:US6001816 (1999).
78. Morsy, M., Gu, M., Zhao, J.Z., Caskey, T. C., Kochanek, S.: US6630346 (2003).
79. Morsy, M.A., Gu, M.C., Zhoa, J., Caskey, T. C., Kochanek, S.: US20030215423 (2003).
80. Muzzin P, Eisensmith RC, Copeland KC, Woo SL. Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc Natl Acad Sci USA 1996; 93: 14804-14808.
81. Matarese G, La Cava A. Immune responses in obesity models. Drug Discov Today Dis Mod 2005;2:177-181.
82. Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: Deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci 2003; 8: 464-476.
83. Sivitz WI, Wayson SM, Bayless ML, et al. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 2003;88:1543-1553.
84. Eriksson A, Attval S, Bonnier M, Eriksson JW, Rosander B, Kalrsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab 2007;9:483-489.
85. Tasci I, Erdem G, Ozgur G. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 2009;204:222-228.
86. Cawthorne, A. M., Stocker, J. C.:US20050065078 (2005).
87. Dhillon H, Kalra SP, Kalra PS. Dose-dependent effects of central leptin gene therapy on genes that regulate body weight and appetite in the hypothalamus. Mol Ther 2001;4: 139-145.
88. Kalra SP. Global life-long health benefits of repression of hypothalamic NPY system by central leptin gene therapy. Curr Top Med Chem 2007; 7: 1675-1681.
89. Kalra SP, Kalra PS. Subjugation of hypothalamic NPY and cohorts with central leptin gene therapy alleviates dyslipidemia, insulin resistance, and obesity for life-time. EXS 2006; 95: 157-169.
90. Depaoli, A. M., Taylor, S. I., Oral, E. A., Garg, A.: US7183254 (2007).
91. Depaoli, Al. M., Taylor, S. I., Oral, E. A., Garg, A.: US20070099836 (2007).
92. Depaoli, A. M., Taylor, S. I., Oral, E. A., Garg, A.: US20050020496 (2005).
93. Brennan AM, Lee JH, Tsiodras S, et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: Observational and interventional studies in humans. Eur J Endocrinol 2009; 160:173-176.
94. Chan JL, Mantzoros CS. Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis. Pituitary 2001; 4: 87-92.
95. Moschos S, ChanJL, Mantzoros CS. Leptin and reproduction: A review. Fertil Steril 2002; 77: 433-444.
96. McMillen IC, Edwards LJ, Duffield J, Muhlhausler BS. Regulation of leptin synthesis and secretion before birth: Implications for the early programming of adult obesity. Reproduction 2006; 131: 415-427.
97. Kitawaki J, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K, Honjo H. Expression of leptin receptor in human endometrium and fluctuation during the menstrual cycle. J Clin Endocrinol Metab 2000; 85: 1946-1950.
98. Tanaka T, Utsunomiya T, Bai T, Nakajima S, Umesaki N. Leptin inhibits decidualization and enhances cell viability of normal human endometrial stromal cells. Int J Mol Med 2003; 12: 95-98.
99. Caprio M, Fabbrini E, Isidori AM, Aversa A, Fabbri A. Leptin in reproduction. Trends Endocrinol Metab 2001;12: 65-72.
100. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996; 12: 318-320.
101. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004; 351: 987-997.
102. Chehab, F. F.: US5773416 (1998).
103. Barkan, D., Dekel, N., Rubinstein, M., Hurgin, V.: US20050065080 (2005).
104. Illmensee, K.O., Dieplinger, H.: US20020137100 (2002).
105. Mantzoros CS, Cramer DW, Liberman RF, Barbieri RL. Predictive value of serum and follicular fluid leptin concentrations during assisted reproductive cycles in normal women and in women with the polycystic ovarian syndrome. Hum Reprod 2000;15: 539-544.
106. Duggal PS, Van Der Hoek KH, Milner CR, et al. The in vivo and in vitro effects of exogenous leptin on ovulation in the rat. Endocrinology 2000; 141:1971-1976.
107. Snodgrass, R. H., Cioffi, J., Zupancic, T. J., Shafer, A. W.: US6355237 (2002).
108. Snodgrass, R. H., Cioffi, J., Zupancic, T. J., Shafer, A.W.: US6838079 (2005).
109. Snodgrass, R. H., Cioffi, J., Zupancic, T. J., Shafer, A. W.: US20020197232 (2002).
110. Brennan, M. B., Hochgeschwender, U.: US6716810 (2004).
111. Auerbach, B. J., Bratton, L. D., Filzen, G. F., Geyer, A. G., Trivedi, B. K., Unangst, P. C.: US6939875 (2005).
112. Auerbach, B. J., Bratton, L. D., Filzen, G., Geyer, A. G.,Trivedi, B. K., Unangst, P. C.: RE39916 (2007).
113. Snodgrass, R. H., Cioffi, J., Zupancic, T.J., Shafer, A. W.: US20050266486 (2005).
114. Auerbach, B. J., Bratton, L. D., Filzen, G. F., Geyer, A.G., Trivedi, B. K., Unangst, P. C.: US20050113440 (2005).
115. Auerbach, B. J., Bratton, L. D., Filzen, G. F., Geyer, A.G., Trivedi, B. K., Unangst, P.C.: US20030225158(2003).
116. Ilan, Y., Elinav, E.: US20060079443 (2006).
117. Barkan, D., Cohen, B., Rubinstein, M.:US7109159 (2006).
118. Ilan, Y., Elinav, E.:US20060079442 (2006).
119. Iwamoto, Y.:US20060040861 (2006).
120. Sierra-Honigmann, R.M.:US7261881 (2007).
121. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000; 68: 437-446.
122. Sierra-Honigmann, M. R.:US20070275874 (2007).
123. Funanage, V. L., Hassink, S. G., Kirwin, S. M., O'Connor, D.: US6884777 (2005).
124. Pothoulakis, C., Mantzoros, C.:US20040229783 (2004).
125. Schwartz, M., O'Connor, D.:US6630444 (2003).
126. Karsenty, G., Ducy, P., Amling, M.:US20040202652 (2004).
127. Karsenty, G., Takeda, S., Elefteriou, F.: US20060165683 (2006).
128. Ke, H., Steppan, Claire, M., Swick, Andrew G.:US6352970 (2002).
129. Ke, H., Steppan, Claire, M., Swick, Andrew G.: US20020019351 (2002).
130. Tezapsidis, N.:US20070066527 (2007).
131. Oomura, Y., Hori, N., Shiraishi, T., Sasaki, K., Takeda, H., Tsuji, M., Matsumiya, T.:US6518235 (2003).
132. Snodgrass, R. H., Cioffi, J., Zupancic, T.J., Shafer, A.W.: US5882860 (1999).
133. Gallaher, D.D., Freiburger, L.: US6899892 (2005).
134. La Cava A, Alviggi C, Matarese G. Unrevealing the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004: 82: 4-11.
135. Flier, J.S., Bjorbaek, C.:US20040087530 (2004).
136. Carpenter, L. R., Stahl, N., Yancopoulos, G.D.: US20020012949 (2002).
137. Snodgrass, R.H., Cioffi, J., Zupancic, T. J., Shafer, A.W.: US6953670 (2005).